CA
CHI Advisors Portfolio holdings
AUM
$252M
This Quarter Return
+35.58%
1 Year Return
+57.46%
3 Year Return
+78.52%
5 Year Return
–
10 Year Return
–
AUM
$133M
AUM Growth
+$133M
(+29%)
Cap. Flow
-$4.34M
Cap. Flow
% of AUM
-3.28%
Top 10 Holdings %
Top 10 Hldgs %
99.02%
Holding
13
New
–
Increased
5
Reduced
6
Closed
1
Top Buys
| 1 |
BPMC
Blueprint Medicines
BPMC
|
$641K |
| 2 |
Ultragenyx Pharmaceutical
RARE
|
$619K |
| 3 |
Ovid Therapeutics
OVID
|
$484K |
| 4 |
Cogent Biosciences
COGT
|
$108K |
| 5 |
Kezar Life Sciences
KZR
|
$24.7K |
Top Sells
Sector Composition
| 1 | Healthcare | 50.16% |
| 2 | Communication Services | 49.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
LVGO
1
DELISTED
Livongo Health, Inc. Common Stock
LVGO
| $66.1M | 49.84% | 2,636,640 | – | – |
|
|
ORTX
2
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $40.7M | 30.68% | 2,958,492 -31,719 | -1% | -$436K |
|
3
Precision BioSciences
DTIL
$57.8M
| $12.3M | 9.24% | 882,358 -201,428 | -19% | -$2.8M |
|
|
4
Ovid Therapeutics
OVID
$91M
| $3.5M | 2.64% | 843,931 +116,671 | +16% | +$484K |
|
|
BPMC
5
DELISTED
Blueprint Medicines
BPMC
| $2.08M | 1.57% | 26,000 +8,000 | +44% | +$641K |
|
6
Corvus Pharmaceuticals
CRVS
$428M
| $2.01M | 1.52% | 370,307 -20,000 | -5% | -$109K |
|
|
7
Ultragenyx Pharmaceutical
RARE
$2.89B
| $1.64M | 1.24% | 38,500 +14,500 | +60% | +$619K |
|
|
GBT
8
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $1.59M | 1.2% | 20,000 -8,000 | -29% | -$636K |
|
|
MYOK
9
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $729K | 0.55% | 10,000 -12,464 | -55% | -$909K |
|
|
BLUE
10
DELISTED
bluebird bio
BLUE
| $702K | 0.53% | 8,000 -4,000 | -33% | -$351K |
|
|
11
Cogent Biosciences
COGT
$1.69B
| $678K | 0.51% | 940,805 +150,000 | +19% | +$108K |
|
|
12
Kezar Life Sciences
KZR
$28.9M
| $619K | 0.47% | 154,255 +6,163 | +4% | +$24.7K |
|
|
BOLD
13
DELISTED
Audentes Therapeutics, Inc
BOLD
| – | – | -35,000 | Closed | -$983K |
|